Madison, WI, USA and Penzberg, Germany, October 22, 2013 / B3C newswire / - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that The Centre for Genomic Research (CGR) at the University of Liverpool in the United Kingdom, has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. The CGR achieved certification to conduct next-generation sequencing target enrichment services with customer samples using the NimbleGen SeqCap EZ workflow. The CGR facility is the first CSP authorized in the UK to provide SeqCap EZ target enrichment services.
“We are pleased to welcome the highly respected Centre for Genomic Research at the University of Liverpool as Certified Service Provider for our SeqCap EZ target enrichment technology,” said Dan Zabrowski, Head of Roche Sequencing Unit. “This program demonstrates our commitment to providing convenient solutions for our customers. The CGR, just like our other global CSPs, will bring their extensive experience in targeted sequencing to servicing the needs of the research community.”
"The CGR has been using NimbleGen enrichment technology for applications as diverse as human exome sequencing and targeted capture of plant genomes. We have been impressed with the results and the performance of the platform,” said Professor Neil Hall, PhD, Co-director of the CGR Facility, “We are delighted to receive the CSP status and look forward to working closely with Roche NimbleGen to provide the best solutions for our collaborators."
For more information about Roche NimbleGen, please visit www.nimblegen.com
About the Centre for Genomic Research at the University of Liverpool
The Centre for Genomic Research performs world-class research at the leading edge of genomic technologies and data analyses. The Centre’s core remit is: To aid the research community to access the full potential of the latest advances in DNA sequencing and bioinformatics methods; and to develop an active, internally driven research program alongside its collaborative service activities. For more information on the CGR, please visit www.liv.ac.uk/cgr.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
NIMBLEGEN and SEQCAP are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.
For further information please contact:
Dr. Claudia Schmitt
Phone: +49 8856 60 10210